Search for an Article

 Search

Articles for category Research

MAC Patient Advisor for Study Advisory Panel

Posted on January 17, 2019   |   
Author: Gretchen   |   
1 Comments   |   
Like 1 Likes

We are looking for 1 additional (male) pulmonary MAC patient advisor for Kevin Winthrop’s PCORI-funded MAC2v3 pragmatic trial!

This is a remote advisor position, no travel for in-person meetings. Note that while this is a 5-year project, a full 5-year commitment to participate is not required. We have 4 patient advisors already identified, and are looking for 1 more to round out the panel.

This study is titled Comparison of two- versus three-antibiotic therapy for pulmonary Mycobacterium avium complex disease (“MAC2v3”). We will prospectively follow patients newly diagnosed with NTM who are randomized to either a 2-drug or 3-drug treatment regimen. Our objective is to determine whether or not a 2-drug treatment regimen is better tolerated and as effective (based on culture analysis) as a 3-drug regimen.

Read More

Tags: MAC NTM NTM Research Patient Advisor
Categories: Research

Physician Update on Respiratory Disease Treatment: Inhaled Corticosteroids vs. Oral Antibiotics

Posted on September 12, 2018   |   
Author: Gretchen   |   
2 Comments   |   
Like 4 Likes

This blog post was written by Beth McKnight, Patient Advocate, with the help of a Patient Advisory Panel.

Researchers at Oregon Health and Science University have found that long-term treatment of respiratory diseases with inhaled corticosteroid drugs actually increases the risk of serious lung infections.

The study, presented at the 2018 American Thoracic Society International Conference, focused on adult patients with bronchiectasis, whose bronchial tubes are thickened from inflammation and infection, preventing the clearing of mucus. Bronchiectasis, most accurately diagnosed by a CT scan, is on the rise in the U.S.

Dr. Emily Henkle, presenting author, said the team found that inhaled corticosteroid use increased the risk of hospitalized infections, and no evidence exists that they prevent exacerbations or progression of the disease. The study examined Medicare data from 90,000 patients who used either inhaled corticosteroids or the oral antibiotics azithromycin and erythromycin. The study found an increased 39% risk in the corticosteroid group as compared the group taking the oral antibiotics.

However, Dr. Henkle cautioned, potential risks exists with taking just one antibiotic long-term, such as the development of antibiotic resistant bacterial lung diseases like Mycobacterium aviumcomplex (MAC or MAI) and other nontuberculous mycobacterial infections.

What does this mean for physicians who treat patients with bronchiectasis and other lung diseases?

Read More

Tags: Bronchiectasis Bronchiectasis Treatment inhaled corticosteroid drugs MAC oral antibiotics
Categories: Research

World Bronchiectasis Conference 2018-Patient Session Recordings

Posted on August 27, 2018   |   
Author: Gretchen   |   
1 Comments   |   
Like 2 Likes

Chronic illness affects every aspect of a patient’s life. Research and new therapies are essential to improve the health and well being of those affected with chronic illnesses. 

Georgetown University and MedStar Health recently held patient sessions at the World Bronchiectasis Conference this past July. Experts in the field were brought together to discuss the newest research focusing on bronchiectasis and nontuberculous mycobacterial lung infections.

If you were unable to attend, we now have the recordings available from the 6 sessions geared toward patients.

If you were able to join, please let us know what you found most valuable as a patient or what you wished to have learned more about. You can post your responses on BRONCHANDNTM360SOCIAL or email us at INFO@BRONCHIECTASISANDNTMINITIATIVE.ORG.

 

 

Read More

Tags: Basics of Bronchiectasis Bronchiectasis Bronchiectasis Treatment Bronchiectasis; NTM; Research NTM Research World Bronchiectasis Conference 2018
Categories: Research

Moving Closer to an Approved Therapy for NTM Lung Disease: FDA Advisory Committee says Arikayce (Inhaled Liposomal Amikacin) is a safe and effective treatment for those with limited options

Posted on August 08, 2018   |   
Author: Gretchen   |   
6 Comments   |   
Like 5 Likes

As you know currently there are no FDA-approved treatments specifically for nontuberculous mycobacterial (NTM) lung disease caused by MAC. Yesterday, the Antimicrobial Drugs Advisory Committee of the U.S. Food & Drug Administration met to assess a newly proposed treatment, Arikayce (Inhaled Liposomal Amikacin) for NTM lung disease caused by Mycobacterium avium complex (MAC).

During the meeting, the Advisory Committee heard presentations from Insmed, the company who developed the treatment, the FDA staff who reviews and analyzes data from the treatment’s clinical trials and from the public. Remarkably, 12 community members traveled to the FDA to tell their stories, each having been allotted 5 minutes during the open public hearing session. The physicians, patients, family members and representatives from the COPD Foundation and our partner, NTMir, spoke of the urgent need for new treatment options that are more effective and less toxic. They explained how NTM has changed their life and what it meant to them to have a better chance at achieving culture conversion, the main benefit of the proposed new treatment.

Their voices, along with the dozens of patients who submitted written comments prior to the meeting, were heard loud and clear and we want to say THANK YOU!

The Advisory Committee was asked to vote on three questions including whether the primary outcome of culture conversion was clinically meaningful, whether the data showed that Arikayce was safe and effective for all NTM lung disease caused by MAC, and whether Arikayce was safe and effective for NTM lung disease cause by MAC in those who have not achieved culture conversion on standard antibiotic regimens. There was a great deal of discussion about what it meant to a patient to have a negative culture and how that translates to feeling better and doing better. In the end, the Committee voted 8 to 6 in support of culture conversion being a meaningful benefit.

Most importantly, the Committee voted 12 to 2 that Insmed had shown that Arikayce was a safe and effective treatment for those who have limited or no other treatment options. Since all of the patients who participated in the trials had already been on standard therapy, the Committee did not vote favorably that it was safe and effective for all patients but further studies that include newly diagnosed or untreated patients could change this in the future.

We are very pleased with the positive outcome that reflects the strong data that Insmed presented for those patients with nowhere else to turn. While this is not the final say in the approval of the therapy, the final decision will be made by the FDA’s Division of Anti-Infective Products, the COPD Foundation is optimistic that they will follow suit after reviewing the data, results, and comments by the research and the patient community.

Read More

Tags: Arikayce FDA Inhaled Liposomal Amikacin Inhaled Therapies NTM
Categories: Research

Upcoming FDA Advisory Committee Meeting for ALIS

Posted on July 12, 2018   |   
Author: Gretchen   |   
1 Comments   |   
Like 4 Likes

The U.S. Food & Drug Administration (FDA) has posted a Federal Register Notice announcing the upcoming Anti-Microbial Advisory Committee Meeting for Insmed’s inhaled liposomal amikacin. The committee will discuss new drug application (NDA) 207356, amikacin liposome inhalation suspension, sponsored by Insmed, Inc., for the proposed indication of treatment of nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex in adults as part of a combination antibacterial drug regimen.

The meeting will take place on August 7, 2018 in the Great Room at the FDA’s White Oak campus (10903 New Hampshire Avenue, Silver Spring, MD).

If you are a patient with MAC lung disease who either did or did not participate in the Insmed clinical trial, and you wish to address the committee during the Open Public Hearing session of the meeting that day, please contact Amy or Susan at ntmmail@ntminfo.org. Please note that the deadline to register as a speaker for the FDA meeting is July 16th, so anyone who is interested should contact them as soon as possible. Compensation will be offered for travel expenses.

It would be most helpful to have two or three patients speak before the committee for 3 to 5 minutes each, addressing the severe unmet need you have as a patient, and how this drug can benefit you. If you participated in the trial, you should also discuss how it helped you, and how it would be beneficial to you to have this drug approved so they can take it.

For those unable to attend the meeting in person or who will not be speaking at the meeting, the FDA offers the opportunity to submit written comments to the docket, no later than July 24, 2018. Statements submitted are public; those submitted before the deadline are printed out and given to committee members with their briefing materials. Comments can be submitted via this link: https://www.regulations.gov/document?D=FDA-2018-N-2490-0001. Just click on the Comment Now! button.

Read More

Tags: FDA Insmed NTM
Categories: Research

Join the FDA Public Workshop on Inhaled Therapies for Bronchiectasis

Posted on June 06, 2018   |   
Author: Gretchen   |   
1 Comments   |   
Like 2 Likes

The Food and Drug Administration is holding a public workshop entitled “Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis” on Wednesday, June 27th from 8:30pm to 4:30pm ET.

The purpose of the public workshop is to discuss the clinical trial design challenges and future considerations for inhaled antibacterial products to treat cystic fibrosis (CF) and non-CF bronchiectasis.

Why tune in? Currently, there are no treatments that the FDA has approved specifically for bronchiectasis. This workshop will help to provide a better pathway forward to developing new treatments for CF and non-CF bronchiectasis patients, including a discussion about what outcomes are the best to measure, how long trails should be, and how resistance issues should be handled.

Make your voice heard! Did you know that the FDA also considers information provided by patients when making decisions about how new devices and treatments are developed and approved? Are you a patient with Non-Cystic Fibrosis Bronchiectasis? You can register to speak at this public hearing and provide the patient perspective on your experiences with the disease, how symptoms have impacted your daily life, and what outcomes matter most to you. You are the expert, and speakers at the workshop and staff at the FDA are seeking your help and guidance in future clinical trial designs and inhaled antibacterial products. To sign up to speak or attend the public workshop, you can register here.

Read More

Tags: Bronchiectasis; NTM; Research FDA NTM Patient Voice Therapies
Categories: Research

Linhaliq/FDA Update

Posted on February 01, 2018   |   
Author: Gretchen   |   
2 Comments   |   
Like 4 Likes

Aradigm, the company that submitted Linhaliq to the FDA for approval, announced that they had received a complete response letter from the FDA stating that they would not approve the treatment at this time.

Over the last several months many of you have communicated with the FDA about the unmet need in the Bronchiectasis community. You told them your priorities, your needs and your frequent battles to keep exacerbations at bay.

While we are disappointed that important patient focused issues were not adequately addressed within the FDA’s response to Aradigm, we believe that your voices will make a difference in moving forward in the quest to identify and approve new treatments for bronchiectasis. We appreciate Aradigm’s commitment to addressing the needs of the bronchiectasis community and will continue to work with all stakeholders to improve the lives of people with bronchiectasis moving forward.

If you would like to read more about Aradigm’s announcement you can view the press release HERE.



Read More

Tags: Bronchiectasis FDA Research Treatments
Categories: Research

The FDA NEEDS to Hear from You!!

Posted on January 23, 2018   |   
Author: Gretchen   |   
0 Comments   |   
Like 5 Likes

The voice of the patient has a role in the drug development AND approval process. In fact, recent legislation mandates an increased emphasis on incorporating the patient perspective into the regulatory process.

Currently, there are no treatments that the FDA has approved specifically for bronchiectasis. On January 11th, 2018 the FDA convened a meeting of the Antimicrobial Drugs Advisory Committee to review the potential new treatment, Linhaliq, made by Aradigm, and make a recommendation to the FDA on whether or not to approve it for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with Pseudomonas aeruginosa lung infections. Linhaliq is an inhaled version of ciprofloxacin that has undergone several clinical trials to evaluate if it extends the time to the first exacerbation compared to a placebo treatment.

This was the second recent Advisory Committee meeting for a potential bronchiectasis therapy coming after a November meeting where the Committee reviewed and did not recommend another version of ciprofloxacin made by Bayer. The discussion and vote at the Linhaliq meeting were based on a specific and narrowly defined question about whether Aradigm had met the standards of safety and efficacy for the drug’s intended outcome, which was time to first exacerbation. Like the Bayer meeting, the committee voted that Aradigm had not met those standards, however the Advisory Committee only provides recommendations for the FDA to consider. The FDA then makes the final decision. However, an approval after a negative committee vote is very rare.

In this case, the process and the discussions that occurred at the meetings do not adequately reflect the needs, priorities and preferences of the patient community. We are asking you to take the time to read the below background information and use the bullet point template as a guide to share your perspective with the FDA as they enter this critical period of determining whether to approve the applications for inhaled ciprofloxacin.

What were the core issues at the Antimicrobial Advisory Committee Meeting?

  • The primary outcome that the FDA and the pharmaceutical companies used was time to first exacerbation which measured whether there was more time until the patient taking the treatment had an exacerbation as compared to those taking the placebo.
  • Time to first exacerbation is not felt to be the most appropriate outcome to use for the bronchiectasis population as it may not adequately reflect whether patients truly do better and feel better on the new treatment. The Advisory Committee even acknowledged this during their discussion.
  • The Committee, the FDA, the pharmaceutical companies, clinicians and patients have acknowledged that frequency of exacerbations is the better outcome measure.
  • The companies also collected data on whether the treatment lowered the frequency of exacerbations, however the Advisory Committee was not allowed to consider this data when deciding whether to recommend approval of the treatment because of the design of the trial and related regulatory review.

 

Read More

Tags: Bronchiectasis Drugs Bronchiectasis Treatment FDA Linhaliq
Categories: Research

Is it possible that eating various foods can slow a lung function decline?

Posted on December 26, 2017   |   
Author: Gretchen   |   
3 Comments   |   
Like 2 Likes

Certain foods may slow declining lung function in smokers, nonsmokers, research suggests

NEWS WEEK (12/21, Matthews) reports that research suggests “certain foods may slow declining lung function both in smokers and nonsmokers.

The ATLANTA JOURNAL-CONSTITUTION (12/21, Parker) reports that investigators examined the diet and lung function of more than 650 adults in 2002, following up with the individuals 10 years later. The study participants completed a questionnaire, which assessed their eating habits, and they also underwent spirometry, a procedure that measures the capacity of lungs to take in oxygen.&

HEALTHY (12/21, Preidt) reports that investigators found that people who ate an average of more than two tomatoes or more than three portions of fresh fruit a day, especially apples, had a slower decline in lung function than those who ate less than one tomato or less than one portion of fruit a day. The link between diet and slower reductions in lung function was even more striking among former smokers, suggesting that nutrients in tomatoes and fresh fruit may help repair lung damage caused by smoking. The FINDINGS were published in the European Respiratory Journal.


 


 

Read More

Tags: healthy eating lung function
Categories: Research

The FDA Wants to Hear From You

Posted on December 21, 2017   |   
Author: Gretchen   |   
2 Comments   |   
Like 3 Likes

The Food and Drug Administration (FDA) is responsible for deciding if new drugs and medical devices are safe and effective based on data typically produced by years of clinical trials. But, did you know that the FDA also considers information provided by patients when deciding whether to approve a new treatment or device?

Currently, there are no treatments that the FDA has approved specifically for bronchiectasis. On January 11th, 2018 the FDA will convene a meeting of the Antimicrobial Drugs Advisory Committee to review the potential new treatment, Linhaliq, and make a recommendation to the FDA on whether or not to approve it for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infections withPseudomonas aeruginosa. The new treatment is made by Aradigm. It is an inhaled version of ciprofloxacin that has undergone several clinical trials to evaluate if it extends the time to the first exacerbation compared to a placebo treatment. The potential to have new treatments indicated specifically for those with chronic lung infections with pseudomonas aeruginosa is particularly important for patients, because patients report a worse quality of life and have more hospital stays when pseudomonas aeruginosa is present.

Only you can truly help the Advisory Committee members who will review the new treatment understand what the unmet medical need is and what living with bronchiectasis is like. What type of impact do frequent lung infections and hospitalizations have on you? How are you currently managing your disease and what type of burden does that treatment place on you? How often do you end up on IV antibiotics every year?

These are just a few of the questions that you can address by participating in an open call for written comments leading up to the January 11th FDA hearing. During the meeting, the Advisory Committee is only able to set aside about an hour for public comments, which means not everyone at the meeting will have the opportunity to speak. Written comments are a great way to ensure that your voice can still be heard and your perspectives on life with bronchiectasis can be considered by the Advisory Committee members. At the end of the meeting, the Advisory Committee members vote on a series of questions that amount to a recommendation on whether the FDA should approve the new treatment. It is then up the FDA to make an official decision, but it is rare that they go against the recommendation of an Advisory Committee, making the opportunity to share your experiences with the disease even more important.

Ready to write a letter to the FDA? Here are a few tips to think about when writing.


Read More

Tags: Bronchiectasis Drugs FDA Medical Devices
Categories: Research

FDA Hearing: Ciprofloxacin Inhalation Powder

Posted on November 17, 2017   |   
5 Comments   |   
Like 13 Likes

This blog post was written by Tracie Sullivan, Grassroots Manager, COPD Foundation.

My first week as a new staff member at COPD Foundation has been an exciting and busy one! Yesterday I had the pleasure of attending the Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee Meeting with six exuberant, welcoming, and passionate advocates. This committee hearing was discussing proposing a new drug application called ciprofloxacin inhalation powder, for reduction of exacerbations in non-cystic fibrosis bronchiectasis in adult patients with respiratory bacterial pathogens. The advisory panel is set up to make recommendations to the FDA about whether or not they should approve a drug. Committee members for this advisory council were made up of 16 individuals composed of doctors, medical professionals, higher education professors, clinical research, mathematical statisticians, consumer and patient representatives.

As the proceedings started, myself and my colleagues learned about the research behind ciprofloxacin inhalation powder, the results from the clinician trials, the biostatistics involved, and clinical safety. Once the afternoon session began, our advocates were able to stand in front of the committee members and share their stories with bronchiectasis. Our advocates included doctors, patients, and caregivers. Those who had been a part of the clinical trials and had seen significant improvements, and those who did not have the opportunity to be a part of the trial, and were looking for new medical treatment opportunities. These stories included the everyday challenges they face, the medical routes they must adhere to, the lifestyle changes they have had to make, and concerns about the lack of research and medical advancements. Each advocate discussed how this new and innovative drug could provide hope for individuals with bronchiectasis, how it could change their lives. How one less exacerbation could keep them out of the emergency room, could allow them to go to that family event they had missed years before, how their quality of life could be instrumentally improved.

Read More

Tags: Advocacy Bayer Cipro FDA
Categories: Research Support

Event Alert: Bronchiectasis and NTM Town Hall Teleconference

Posted on October 24, 2017   |   
Author: Gretchen   |   
5 Comments   |   
Like 11 Likes

The COPD Foundation is excited to announce that we will be convening a 2-part town hall teleconference series about bronchiectasis and NTM. The first town hall teleconference is titled Bronchiectasis and NTM 101: The Basics and will be convened on Thursday, December 7, 2017 from 1:00pm to 2:00pm EST. This town hall teleconference will provide an opportunity for community members to learn the basics about bronchiectasis and NTM, as explained by expert speaker Dr. Kevin Winthrop of Oregon Health and Science University. The event will allow also for the opportunity for community members to ask Dr. Winthrop questions about bronchiectasis and/or NTM. Topics to be covered during this event are listed in the agenda below. We're looking forward to having you join us on our first-ever Bronchiectasis and NTM Town Hall Teleconference. Please REGISTER FOR THE EVENT HERE and mark your calendars accordingly!

Bronchiectasis and NTM 101: The Basics

1:00 – 1:05 pm Welcome and Introduction COPD Foundation

1:05 – 1:20 pm An Overview of Bronchiectasis and NTM Kevin Winthrop, MD

- What are bronchiectasis and NTM? How do they relate?

- What causes these conditions?

- What are common symptoms of these conditions?

1:20-1:30 pm  Questions and Answers

1:30-1:45 pm  An Overview of Bronchiectasis and NTM cont’d – Kevin Winthrop, MD

- How are these conditions diagnosed?

- How are these conditions treated?

- What resources are available for patients?

1:45-1:55 pm  Questions and Answers

1:55-2:00 pm  Closing Remarks – COPD Foundation

The second part of this town hall teleconference series will take a more in-depth dive into bronchiectasis and NTM and will be convened in early 2018. More details to come soon!


 

Read More

Tags: Bronchiectasis Conference COPD Foundation
Categories: Research

1 2
Sign In to Participate
Or register to become a member